Mueller Susanne G, Weiner Michael W, Thal Leon J, Petersen Ronald C, Jack Clifford, Jagust William, Trojanowski John Q, Toga Arthur W, Beckett Laurel
Department of Radiology, University of California, San Francisco, CA, USA.
Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii. doi: 10.1016/j.nic.2005.09.008.
With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.
随着发达国家人均寿命的延长，阿尔茨海默病（AD）的发病率及其社会经济影响正在不断增加。对AD发病机制的深入了解有助于制定旨在减缓或预防神经元死亡的治疗策略。使用临床结局指标的AD治疗试验需要较长的观察时间和大量的患者样本。越来越多的证据表明，神经影像学、脑脊液和血液生物标志物可能提供有助于减少样本量和观察期的信息。阿尔茨海默病神经影像学计划将有助于确定临床、神经影像学和生物标志物结局指标，这些指标在测量纵向变化和预测病情转变方面具有最高的效能。
